Complement Component C1q as a Potential Diagnostic Tool for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Subtyping.
Castro-Marrero, Jesús, Zacares, Mario, Almenar-Pérez, Eloy et al. · Journal of clinical medicine · 2021 · DOI
Quick Summary
Researchers analyzed blood samples from 250 women with ME/CFS to see if specific blood markers could help identify different types of the disease. They found that about 43% of participants had high levels of a protein called C1q, which was particularly associated with those experiencing more pain symptoms. This discovery suggests that blood tests might one day help doctors identify which ME/CFS patients belong to which subgroup, potentially leading to better tailored treatments.
Why It Matters
ME/CFS currently lacks objective diagnostic tests and relies entirely on clinical symptoms, making diagnosis challenging and variable across providers. Identifying blood-based markers like C1q could enable earlier, more accurate diagnosis and reveal disease subtypes that might respond differently to treatments. This work provides a foundation for developing laboratory tests that could revolutionize ME/CFS clinical management and accelerate targeted research.
Observed Findings
Three symptom-based clusters (severe, moderate, mild) were identified with statistically significant differences in five blood parameters.
Circulating C1q was elevated in 107 of 250 participants (43%).
Elevated C1q was associated with an ME/CFS subtype characterized by more apparent pain symptoms.
Significant differences (p < 0.05) in blood analytics distinguished the three symptom-based clusters.
Inferred Conclusions
C1q is a key molecule for identifying a distinct ME/CFS subtype with prominent pain manifestations.
Blood analytics, when analyzed using combinatorial approaches on large cohorts, can identify disease subtypes and differentiate between clinical presentations of ME/CFS.
C1q may serve as a valuable diagnostic tool for future implementation in clinical ME/CFS diagnosis and patient stratification.
Remaining Questions
Does C1q elevation occur in men with ME/CFS, or is this pattern specific to women?
Is elevated C1q a cause, consequence, or secondary marker of ME/CFS pathology?
Can C1q levels predict disease progression, treatment response, or prognosis in longitudinal follow-up?
What This Study Does Not Prove
This study does not prove that C1q causes ME/CFS or pain symptoms—it only shows an association in this cross-sectional snapshot. The findings are specific to women and cannot be assumed to apply to men with ME/CFS. The study does not establish whether C1q elevation is a consequence of ME/CFS, a contributing factor, or an unrelated marker in a subgroup.